All News

Insulin glargine-yfgn is the first interchangeable biosimilar product for the treatment of diabetes approved in the United States, which can provide patients with alternative, equally effective options for treating diabetes that could be more cost effective.

Workflow in the clinic and the pharmacy are critical for the implementation of a new and novel medication therapy, such as cabotegravir-rilpivirine.

Chad Hatfield, PharmD, MHA, BCPS, chief pharmacy officer at UC Davis Medical Center, discusses how data points used in oncology pharmacy practice and how it is collected.

Blood pressure has to be monitored closely in patients diagnosed with stage 1 or 2 hypertension.

FDA approvals of vaccines usually take 10 to 15 years, but the pandemic necessitates emergency action.

A majority of pharmacy departments are presently conducting safety huddles within their teams.

Both researchers received $30,000 to fund projects that demonstrate the ways that new and emerging technologies can assist in the safe and effective use of medications.

Based on their findings, investigators said modifiable risk factors are strongly associated with C-reactive protein levels in patients with coronary artery disease.

The open label trial was available to patients 18 years of age and older with relapsed or refractory DLBCL after 2 or more lines of treatment.

A pooled analysis of a 48-week open-label extension of a pair of phase 3 studies found that 99% of patients with HIV who initiated treatment using bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets maintained an undetectable viral load through 4 years of follow-up.

AQP-modulating agent discovery has proved challenging, but many powerful AQP3 permeating molecules have been identified.

Individuals with attention-deficit hyperactivity disorder and other diagnoses who are taking stimulant medications are also more likely to switch to non-stimulant medications.

Pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in OS for patients whose tumors expressed PD-L1 with a combined positive score ≥10 compared to chemotherapy alone, according to the study.

These services include vaccinations, routine screenings, and physical exams.

Older drugs such as lovastatin (Mevacor, Altoprev), simvastatin (Zocor), and atorvastatin (Lipitor) have the most drug interactions.

Investigators hypothesize that concurrent symptoms of anxiety and depression may be linked to concerns about adverse events.

Officials with the CDC updated their COVID-19 guidelines today, urging that vaccinated individuals in areas of substantial and high transmission wear masks in public indoor spaces, including schools, in order to prevent the spread of the Delta variant.

Many pharmacists must find a way to vaccinate hundreds of patients in an organized way, while still having to run an understaffed pharmacy.

John M. O’Brien, PharmD, MPH, newly appointed President and CEO of the National Pharmaceutical Council, discussed his history prior to joining NPC.

The clinical trial expansion is part of efforts to detect potential adverse effects in children, such as heart inflammation problems.

According to the investigators, this discrepancy remains even if the individual reported symptoms of heart failure during a routine outpatient health care appointment within the past 6 months.

Theresa McArdle, MBA, senior brand marketing manager at Pharmavite, to discuss new survey data that showed a decline in self-care among pharmacists coming out of the COVID-19 pandemic.

Ken Perez, MBA, vice president of healthcare policy and government affairs at Omnicell, discussed the pandemic's impact on the legislative push to grant pharmacists provider status for Medicare Part B.

The combination of pembrolizumab and chemotherapy marks the first immunotherapy regimen approved for patients with high-risk early-stage triple-negative breast cancer.

Pharmacy Times interviewed Craig Freyer, PharmD, BCOP, and Andrew Lin, PharmD, BCOP, to discuss the updates in the prevention and treatment of cytokine release syndrome and neurologic toxicities for patients with multiple myeloma.

Evkeeza has been approved as an adjunct to other low-density lipoprotein cholesterol-lowering therapies to treat patients 12 years and older with homozygous familial hypercholesterolemia.

According to the investigators, treatment with ruxolitinib resulted in a significant improvement in ORR after 24 weeks, with an ORR of 49.7% in the ruxolitinib arm compared to 25.6% in the best available therapy arm.

Two of the studies also found that patients with COVID-19 who received remdesivir had a significantly increased chance of discharge from the hospital by day 28.